TransMedics Q2 Revenue Beats, But Net Income Drops on R&D Spend
TMDX sits 46% above its 52-week low of $60.105.
Summary
TransMedics reported Q2 revenue of $189.9M, beating the $183.64M consensus, but net income fell to $14.7M from higher R&D and infrastructure spending. Gross margin compressed to 60% due to a shift toward service revenue and temporary product-cost headwinds. The company raised the low end of its FY26 revenue guidance to $737M-$757M, excluding PAD Aviation, which was already reported earlier today. The full earnings release adds color on the margin pressure and the drivers behind the revenue beat—increased OCS utilization in liver and heart transplants. The stock had already moved on the guidance raise; the margin details may temper enthusiasm.
At the time of this announcement, TMDX was trading at $88.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $60.11 to $156.00. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.